

June 18, 2021

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra — Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
Luxembourg Stock Exchange Bourse de Luxembourg BP 165, L-2011 Luxembourg Siege social 11, avenue de la Portal - Neuve	London Stock Exchange 10 Paternoster Square London EC4M 7LS United Kingdom

Sub: Disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended on March 31, 2021

Dear Sir/Madam

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we hereby submit the disclosure of Related Party transactions, on a consolidated basis for the half year ended March 31, 2021.

Kindly take the above on your records.

Thanking you,
Yours faithfully,

For Orchid Pharma Limited

Nikita K
Company Secretary

Consolidated disclosure of Related Party Transaction & balances for the Half year ended March 31, 2021

Related party disclosure

a) Nature of Related party

Holding company Dhanuka Laboratories Limited

Subsidiary Companies Orchid Europe Limited, UK
Orchid Pharmaceuticals Inc., USA
Orgenus Pharma Inc., USA
(Subsidiary of Orchid Pharmaceuticals Inc USA.)
Orchid Pharma Inc / Karalex Pharma USA
(Subsidiary of Orchid Pharmaceuticals Inc, USA)
Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa
Bexel Pharmaceuticals Inc. USA
Diakron Pharmaceuticals Inc., USA

Key Management Personnel and their relatives

Mr. Ram Gopal Agarwal : Chairman and Non-Executive director (w.e.f. June 29, 2020)
Mr. Manish Dhanuka* : Managing Director (w.e.f. June 29, 2020)
Mr. Mridul Dhanuka* : Whole time Director (w.e.f. June 29, 2020)
Mr. Arun Kumar Dhanuka : Non-Executive Director (w.e.f. March 31, 2020)
Mr. Sunil Gupta : Chief Financial Officer (w.e.f. June 29, 2020)
Ms. Nikita K : Company Secretary

* Joined the Board as Director with effective from March 31, 2020

Related party under section 2(76) (iii) and 2(76) (iv) of companies Act, 2013 Synmedic Laboratories
Otsuka Chemical (India) Private Limited

Transactions with related parties are as follows (October 01, 2020 to March 31, 2021)

Particulars	Nature of Relation Ship	Nature of Transaction	Amount in INR Lakhs
Dhanuka Laboratories Limited	Holding Company	Purchase of Goods	365.82
Otsuka Chemical (India) Private Ltd	Related Party under 2(76)(iv)	Purchase of Goods	2,358.98
Orchid Pharma INC	Subsidiary Company	Sale of Goods	603.17

M. Dhanuka

S.K. G. Dhanuka

Synmedic Laboratories	Related Party under sec2(76)(iii)	Sale of Goods	-
Orchid Europe Limited	Subsidiary Company	Services	-
Managing Director, Whole Time Directors and Company Secretary	Key Management Personnel	Compensation (short term employee benefit)	72.22
Shri Ram Gopal Agarwal and Shri Arun Kumar Dhanuka	Non-Executive Directors	Sitting Fee	0.75

Balances with related parties are as follows (As on 31st March 2021)


Particulars	Nature of Relation Ship	Nature of Transaction	Amount in INR Lakhs
Dhanuka Laboratories Limited	Holding Company	Trade Payable	74.56
Otsuka Chemical (India) Private Ltd	Related Party Under Sec 2(76)(iv)	Trade Payable	340.42
Orchid Europe Limited	Subsidiary Company	Trade Payable	31.12
Orchid Pharma INC	Subsidiary Company	Trade Receivables	3,413.91
Synmedic Laboratories	Related Party Under Sec 2(76)(iii)	Trade Receivables	4.30
Dhanuka Laboratories Limited	Holding Company	0% Optionally Convertible Debentures	14,300.00

For Orchid Pharma Limited


Manish Dhanuka
Managing Director



For Orchid Pharma Limited


Sunil Kumar Gupta
Chief Financial Officer